As demand for self-injection devices such as auto injectors and pen injectors continues to rise, drug delivery device suppliers must design manufacturing operations that are scalable, especially for key capabilities such as moulding and material handling systems.
SHL, a leader in this field, has strived to ensure that capacity is always available to adapt to the changing demands of the market and to satisfy the risk mitigation requirements of our clients.
SHL general manager Frank Isaksson commented on the recent expansion activities at SHL facilities.
"We have worked closely with our suppliers to design each of our facilities for maximum scalability," he said. "Just recently we added several new lines of moulding machines and also installed additional material handling systems.
"In fact, our facility management team will have new production areas set up for expansion well in advance of receiving any equipment. And, based on our experience, will always be expanding our moulding and material handling systems, in addition to tooling, metrology and automation.
"Knowing this now, we can prepare in advance. The teams involved in these areas are experienced and always looking into ways to optimise production and introduce new technologies to maximise output. In addition, we continue to invest heavily in employee-centric training programs for experienced staff and newcomers, as well as forward looking intern and apprentice programmes."
What all this means to biopharmaceutical customers is that SHL will have the capacity to produce auto injectors, pen injectors and inhaler systems even if demand increases beyond initial forecasts. Communication between all partners is vital regarding ongoing forecasts, especially with several injectable biologics commanding valuations in the several billions US dollars.